B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRIA4

MOLECULAR TARGET

glutamate ionotropic receptor AMPA type subunit 4

UniProt: P48058NCBI Gene: 289310 compounds

GRIA4 (glutamate ionotropic receptor AMPA type subunit 4) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRIA4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1kainic acid3.8144
2nbqx3.5634
3s ampa3.0019
4rs ampa3.0019
5alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid2.8917
6Glutamic Acid2.7114
7Glutamic Acid2.7114
8tezampanel anhydrous2.7114
9aniracetam0.691
10Piracetam0.691

About GRIA4 as a Drug Target

GRIA4 (glutamate ionotropic receptor AMPA type subunit 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented GRIA4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRIA4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.